Analysts’ Viewpoint
The neonatal respiratory distress syndrome treatment market is expected to witness significant growth in the next few years owing to rise in incidence of premature births and technological advancement in neonatal care. Increase in birth rate, especially in developing countries, is further contributing to the neonatal respiratory distress syndrome treatment market development.
Key market contributors are investing in research and development to develop new and innovative treatments for NRDS, and grabbing incremental neonatal respiratory distress syndrome treatment business opportunities. Surfactant therapy, extracorporeal membrane oxygenation (ECMO), and high-frequency ventilation are some of the effective NRDS treatments gaining tremendous traction worldwide. However, lack of trained healthcare personnel and limited availability of specialized NRDS treatment centers are expected to hamper market statistics during the forecast period.
Neonatal respiratory distress syndrome (NRDS) is a condition that affects newborns, especially premature infants. It occurs when the newborn's lungs are not fully developed and are unable to produce enough surfactant ‒ a substance that helps keep the air sacs in the lungs open. Consequently, newborns experience difficulty in breathing. They may experience rapid, shallow breathing, and skin becomes bluish due to lack of oxygen.
Respiratory distress syndrome (RDS) is a serious condition that can lead to complications such as pneumonia, brain damage, and, in severe cases, death. Treatment for RDS typically involves providing the newborn with supplemental oxygen and, in some cases, mechanical ventilation to help the newborn breathe. In some cases, surfactant replacement therapy may be used to supplement the newborn's natural surfactant production. The treatment for NRDS typically involves, mechanical ventilation, surfactant replacement therapy, and supportive care.
Premature birth is a major risk factor for neonatal respiratory distress syndrome, as premature infants are more likely to develop the condition due to their underdeveloped lungs.
Rise in number of premature births, globally, is contributing to the corresponding increase in the incidence of RDS, thereby driving the demand for neonatal respiratory distress syndrome treatment. This factor is likely to propel the future of neonatal respiratory distress syndrome treatment market during the forecast period.
According to the World Health Organization, approximately 15 million babies are born prematurely each year. Preterm birth affected approximately one out of every ten infants born in the U.S. in 2021. The rate of preterm birth increased by 4% in 2021, from 10.1% in 2020 to 10.5% in 2021.
Advancements in neonatal care have been driving the growth of the neonatal respiratory distress syndrome (RDS) market. The survival rate of premature infants with RDS has increased due to improved diagnostic methods and treatments, which in turn is fueling the demand for neonatal care services.
Various leading companies play a key role in the development of new treatments and technologies to cure respiratory distress syndrome (RDS) in newborns. For instance, Smiths Medical is a medical device company that offers neonatal care products, including neonatal ventilators and respiratory support devices for RDS.
Babies have survived longer and with less lung damage since the introduction of volume-targeted ventilators. These babies require ventilator support for shorter periods of time and have a lower risk of developing pneumothorax. Volume-targeted ventilators aid in the maintenance of more stable carbon dioxide levels in blood and the reduction of brain ultrasound abnormalities. However, more research is needed to determine whether volume-targeted ventilators improve movement and intellect development in these babies.
The surfactant therapy is one of the lucrative neonatal respiratory distress syndrome treatment market segments. It is expected to dominate the global market in the next few years.
Surfactant therapy is a treatment for neonatal respiratory distress syndrome (RDS) that involves the administration of artificial surfactants to premature infants with underdeveloped lungs. The surfactant is designed to mimic the natural surfactant that is produced by the lungs and helps keep the air sacs in the lungs open, reducing the risk of collapse, and ensuring adequate oxygenation.
Surfactant therapy is typically administered via a tube inserted into the baby's trachea. It has been shown to be effective in reducing the severity of RDS, reducing the need for mechanical ventilation, and improving survival rates among premature infants. Surfactant therapy is used in conjunction with oxygen therapy, and is only administered to infants who are not responding adequately to oxygen therapy alone.
Followed by surfactant therapy, the oxygen therapy segment accounted for major market share of the global neonatal RDS treatment market. Oxygen therapy is considered a major treatment for neonatal RDS and is widely used to provide adequate oxygenation to premature infants with underdeveloped lungs. Other treatments such as surfactant replacement therapy and mechanical ventilation are also available; however, oxygen therapy remains the most commonly used treatment for neonatal RDS.
According to the global neonatal respiratory distress syndrome treatment market analysis report, the hospitals segment is projected to account for major share of the global market during the forecast period. Hospitals are equipped with the necessary facilities, equipment, and trained medical staff to provide neonatal intensive care and treat premature infants with RDS.
The use of oxygen therapy, surfactant therapy, and mechanical ventilation for the treatment of neonatal RDS is typically performed in hospital settings, making hospitals the primary providers of neonatal RDS treatment. Additionally, numerous premature infants with RDS require hospitalization and ongoing medical care, further driving the demand for neonatal RDS treatment in hospital settings.
North America is likely to dominate the global neonatal respiratory distress syndrome treatment market during the forecast period. The neonatal respiratory distress syndrome treatment market size in the region is projected to increase in the near future, owing to the availability of advanced healthcare infrastructure, high incidence of premature births, and increased healthcare expenditure. Additionally, the presence of major players in the region along with rise in availability of innovative treatments for NRDS is also contributing to market expansion.
Additionally, the neonatal respiratory distress syndrome treatment market in Asia Pacific is expected to grow significantly in the next few years. This growth can be attributed to increase in birth rates, rise in awareness about NRDS treatment, and growth in the healthcare industry in the region. Additionally, the presence of developing countries in the region, such as India and China, with large populations and improving healthcare systems, is also expected to augment the neonatal respiratory distress syndrome treatment market value in the near future. However, limited access to advanced medical treatments and lower healthcare expenditure in some parts of the region may hinder market progress in the region.
Neonatal respiratory distress syndrome treatment market growth can be ascribed to the increase in adoption of innovative strategies by key market leaders. These market leaders are engaged in expansion of product portfolio and mergers & acquisitions to gain revenue benefits.
Companies including Medtronic, Drägerwerk AG & Co. KGaA, GE HealthCare, Koninklijke Philips N.V., Smiths Medical (ICU Medical, Inc.), Fisher & Paykel Healthcare Limited, IBIO, INC., Windtree Therapeutics Inc., Synthetic Biologics, and Synairgen are contributing to the major neonatal respiratory distress syndrome treatment market share during the forecast period.
The neonatal respiratory distress syndrome treatment industry report profiles key players based on parameters such as financial overview, company overview, business strategies, recent developments, business segments, and product portfolio.
|
Attribute |
Detail |
|
Market Size Value in 2022 |
US$ 780.1 Mn |
|
Market Forecast Value in 2031 |
More than US$ 1.6 Bn |
|
Growth Rate (CAGR) |
7.9% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Mn/Bn for Value |
|
Market Analysis |
It includes segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 780.1 Mn in 2022
It is projected to reach more than US$ 1.6 Bn by 2031
It is anticipated to grow at a CAGR of 7.9% from 2023 to 2031
Development of new and innovative treatments for NRDS, such as surfactant therapy, extracorporeal membrane oxygenation (ECMO), and high-frequency ventilation
North America is projected to account for major market share during the forecast period
Medtronic, Drägerwerk AG & Co. KGaA, GE HealthCare, Koninklijke Philips N.V., Smiths Medical (ICU Medical, Inc.), Fisher & Paykel Healthcare Limited, IBIO, INC., Windtree Therapeutics Inc., Synthetic Biologics, and Synairgen
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Neonatal Respiratory Distress Syndrome Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Technological Advancements
5.2. Key Product/Brand Analysis
5.3. Insights on Prevalence of Respiratory Distress Syndrome in Neonates
5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast, by Therapy
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapy, 2017–2031
6.3.1. Oxygen Therapy
6.3.1.1. Nasal Cannula
6.3.1.2. Continuous Positive Airway Pressure (CPAP)
6.3.1.3. Ventilator
6.3.2. Surfactant Therapy
6.3.3. Others
6.4. Market Attractiveness Analysis, by Therapy
7. Global Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Hospitals
7.3.2. Sub-acute Facilities
7.3.3. Home Care
7.3.4. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America (LATAM)
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Therapy, 2017–2031
9.2.1. Oxygen Therapy
9.2.1.1. Nasal Cannula
9.2.1.2. Continuous Positive Airway Pressure (CPAP)
9.2.1.3. Ventilator
9.2.2. Surfactant Therapy
9.2.3. Others
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Sub-acute Facilities
9.3.3. Home Care
9.3.4. Others
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Therapy
9.5.2. By End-user
9.5.3. By Country
10. Europe Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Therapy, 2017–2031
10.2.1. Oxygen Therapy
10.2.1.1. Nasal Cannula
10.2.1.2. Continuous Positive Airway Pressure (CPAP)
10.2.1.3. Ventilator
10.2.2. Surfactant Therapy
10.2.3. Others
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Hospitals
10.3.2. Sub-acute Facilities
10.3.3. Home Care
10.3.4. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Therapy
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapy, 2017–2031
11.2.1. Oxygen Therapy
11.2.1.1. Nasal Cannula
11.2.1.2. Continuous Positive Airway Pressure (CPAP)
11.2.1.3. Ventilator
11.2.2. Surfactant Therapy
11.2.3. Others
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. Hospitals
11.3.2. Sub-acute Facilities
11.3.3. Home Care
11.3.4. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Therapy
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy, 2017–2031
12.2.1. Oxygen Therapy
12.2.1.1. Nasal Cannula
12.2.1.2. Continuous Positive Airway Pressure (CPAP)
12.2.1.3. Ventilator
12.2.2. Surfactant Therapy
12.2.3. Others
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. Hospitals
12.3.2. Sub-acute Facilities
12.3.3. Home Care
12.3.4. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Therapy
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy, 2017–2031
13.2.1. Oxygen Therapy
13.2.1.1. Nasal Cannula
13.2.1.2. Continuous Positive Airway Pressure (CPAP)
13.2.1.3. Ventilator
13.2.2. Surfactant Therapy
13.2.3. Others
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. Hospitals
13.3.2. Sub-acute Facilities
13.3.3. Home Care
13.3.4. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Therapy
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Medtronic
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Drägerwerk AG & Co. KGaA
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. GE HealthCare
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Fisher & Paykel
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Philips Healthcare
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Smiths Medical (ICU Medical, Inc.)
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
1.3.5. IBIO, INC.
14.3.6.6. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.7. Product Portfolio
14.3.6.8. Financial Overview
14.3.6.9. SWOT Analysis
14.3.6.10. Strategic Overview
14.3.7. Windtree Therapeutics Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Synthetic Biologics
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Synairgen
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Other Prominent Players
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
List of Tables
Table 01: Global Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031
Table 02: Global Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 03: Global Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031
Table 05: North America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: North America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031
Table 08: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031
Table 11: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031
Table 14: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 15: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031
Table 17: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 18: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Therapy, 2022 and 2031
Figure 03: Global Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Therapy, 2023–2031
Figure 04: Global Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 05: Global Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by End-user, 2023–2031
Figure 06: Global Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Region, 2022 and 2031
Figure 07: Global Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Region, 2023–2031
Figure 08: North America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 09: North America Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Therapy, 2022 and 2031
Figure 10: North America Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Therapy, 2023–2031
Figure 11: North America Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 12: North America Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by End-user, 2023–2031
Figure 13: North America Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Country, 2022 and 2031
Figure 14: North America Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Country, 2023–2031
Figure 15: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 16: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Therapy, 2022 and 2031
Figure 17: Europe Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Therapy, 2023–2031
Figure 18: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 19: Europe Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by End-user, 2023–2031
Figure 20: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 21: Europe Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 22: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 23: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Therapy, 2022 and 2031
Figure 24: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Therapy, 2023–2031
Figure 25: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 26: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by End-user, 2023–2031
Figure 27: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 28: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 30: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Therapy, 2022 and 2031
Figure 31: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Therapy, 2023–2031
Figure 32: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 33: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by End-user, 2023–2031
Figure 34: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 35: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 36: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Therapy, 2022 and 2031
Figure 38: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Therapy, 2023–2031
Figure 39: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 40: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by End-user, 2023–2031
Figure 41: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 43: Global Neonatal Respiratory Distress Syndrome Treatment Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Neonatal Respiratory Distress Syndrome Treatment Market
